Simone Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 12 Year, 10 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth 164.27%
- Profit Growth -37.86%
- Ebitda -86.49%
- Net Worth 5.13%
- Total Assets 10.10%
About Simone Life Sciences
Simone Life Sciences Private Limited (SLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 31 March 2012 and has a history of 12 years and ten months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Reena Dalmia and Sushant Nayyar serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74900DL2012PTC233824
- Company No.
233824
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Mar 2012
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Simone Life Sciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Reena Dalmia  | Director | 31-Mar-2012 | Current |
| Sushant Nayyar | Director | 31-Mar-2012 | Current |
Financial Performance of Simone Life Sciences.
Simone Life Sciences Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 164.27% increase. The company also saw a substantial fall in profitability, with a 37.86% decrease in profit. The company's net worth moved up by a moderate rise of 5.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Simone Life Sciences?
In 2018, Simone Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Denzour Nutrition Private LimitedSushant Nayyar is a mutual person
- Msn Medishield Private Limited
Sushant Nayyar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Simone Life Sciences?
Unlock and access historical data on people associated with Simone Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Simone Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Simone Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
